Active, Not Recruiting
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
NCT04208178
- Conditions
- Advanced HER2+Breast Cancer
- Locations
-
- Highlands Oncology Group Fayetteville, Arkansas, United States
- University of California LA Los Angeles, California, United States
- Novartis Investigative Site Leuven, Belgium
- Novartis Investigative Site Liège, Belgium